IL17A and neoplasm: The IYIY-BODIPY mediated IL-17+ cells in this study probably functioned in an antitumor way based on (a) the observed delay in tumor growth post IYIY-I2-BODIPY administration, (b) the reduction of TGF-β which is known to block the production of vascular endothelial growth factor (VEGF, a potent angiogenic factor)48, 49 and, (c) the increase in Th1 and CTL cell populations which have been reported in the presence of IL-1750, 51.